10/01/2026
Breast cancer therapies like anthracyclines and trastuzumab reduce tumor recurrence but carry a risk of treatment-induced heart function changes and and long-term metabolic dysfunction. A University of Alberta team led by Dr. Amy A. Kirkham, Dr. Edith Pituskin and DoM co-investigators Dr. Michael Stickland and Dr. Gavin Y. Oudit (Pulmonary Medicine and Cardiology, respectively) conducted the randomized TITAN trial to test whether a 52-week multidisciplinary cardiac rehabilitation care model—combining risk-factor management, dietary counseling, and supervised exercise—can reduce heart damage during active breast cancer treatment.
While the program didn’t alter the primary endpoint of left ventricular ejection fraction (61% ± 6%) or serum troponin levels compared to usual care, there was substantial lipid risk reduction in the treatment group, with significantly lower total cholesterol (p=0.002) and LDL cholesterol (p